

Personal information:

- Born in Chioggia (VE), Italy on the 30/07/1987; Nationality: Italian

Current situation:

- Medical Oncologist at Department of Medical Oncology 2, Istituto Oncologico Veneto I.R.C.C.S., Padova, Italy from January 2019 to present

Education:

- Medical degree from the University of Padova on the 23/07/2012 with grade 110/110 cum laude
- Diploma from the *Scuola Galileiana di Studi Superiori* (December 2013) with grade 70/70 cum laude (Thesis title: BRAF and KRAS mutational status: impact on resection of liver metastasis in patients affected by colorectal carcinoma)
- *Diploma di Specializzazione in Oncologia Medica* (Specialized Training in Medical Oncology) from the University of Padova (August 2013-August 2018) with grade 110/110 cum laude (Thesis title: The role of tumor biology in predicting response to HER2 dual blockade in early HR+/HER2+ breast cancer: Lessons from the PerElisa Trial")

Clinical activity and specific training:

- Stage at *Service d'Oncologie Medicale della Clinique Saint Luc – UCL Bruxelles* in April 2013
- Clinical training Medical Oncology 2, Istituto Oncologico Veneto I.R.C.C.S., Padova, Italy (08/2013-12/2014 and 01/2015-01/2018 – focus on Breast Cancer)
- Medico Borsista at IOSI – Bellinzona Phase I/II Clinical Trials Unit from 01/01/2014 to 31/12/2014
- 2015 ESMO Preceptorship on Lymphoma (27-28 November 2015, Lugano, Switzerland)
- Visiting Scientist at Prof. Aleix Prat's Lab in Translational genomics and targeted therapeutics in solid tumors (IDIBAPS, Barcelona, Spain) from February 2018 to July 2018

Abstracts, posters and congress presentation (first author and presenter in bold):

- Presentation "ESMO Clinical Practice Guidelines - Gastric marginal zone lymphoma of MALT type - Case presentation" ESMO 2014 Congress (invited oral presentation)
- Coauthor of "A phase I study of the smoothened (SMO) antagonist LDE225 in combination with paclitaxel in patients with advanced solid tumors", "Lurbinectedin (PM01183) in combination with paclitaxel (P) in patients (pts) with advanced solid tumors" and "Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors" accepted as posters at ECC 2015
- Coauthor of "Cut-off analysis and prognostic relevance of Ki67 for resected early stage pure invasive lobular breast carcinoma (ILC)" accepted as poster ASCO Annual Meeting 2016
- Coauthor of "Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)" accepted as poster discussion and "Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion results with or without the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors" accepted as poster at ESMO 2016 Congress
- Poster "**Factors related to the prognosis of breast cancer patients after the development of brain metastases**" accepted as poster (first author and presenter) and co-author of "Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype" accepted as poster at **SABCS 2016**
- Presentation "**La scelta del trattamento adiuvante: utilità clinica dei tests genomici**" **Convegno Nazionale AIOM Giovani 2017**
- Poster "**External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases**" accepted as poster at **ESMO Congress 2017** (first author and presenter)
- Coauthor of "A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure Invasive Lobular Breast Carcinoma (ILC)" accepted as poster at ASCO Annual Meeting 2017
- Poster "**Clinical presentation and outcome of leptomeningeal metastasis in BC patients in relation to histology and tumor subtype**" accepted as poster at **SABCS 2017** (first author and presenter)
- Coauthor of "De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study." Oral presentation at ASCO Annual Meeting 2018
- Coauthor of "Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model." accepted as poster at ASCO Annual Meeting 2018
- Poster "**Oncological outcome of fat grafting for breast reconstruction after cancer**" accepted as poster (first author and presenter) and coauthor of "A propensity score exploring the impact of the addition of adjuvant chemotherapy to hormone therapy in a multi-center series of resected luminal early stage pure invasive Lobular Breast Carcinoma" accepted as poster at **ESMO meeting 2018**
- Poster "**Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy**" accepted as poster (first author and presenter) and co-author of "Independent validation of a combined biomarker based on the PAM50 HER2-enriched subtype and ERBB2 mRNA levels following HER2 blockade without chemotherapy in the PerELISA phase II trial" and "Lapatinib-based therapies after Pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patients" accepted as poster at **SABCS 2018**
- Poster "**ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)**" accepted as poster (first author and presenter) at **ESMO Breast Cancer 2019**

Publications:

- Zulato E, Bergamo F, De Paoli A, **Griguolo G**, Esposito G, De Salvo GL, Mescoli C, Rugge M, Nardin M, Di Grazia L, Lonardi S, Indraccolo S, Zagonel V “**Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab**” **Br J Cancer**. 2014 Jul 1;111(1):25-32.
- **Griguolo G**, Mazzucchelli L, Cavalli F, Ceriani L, Zucca E, Stathis A “**A case of Hodgkin lymphoma in a patient with a history of bone pain and an initial diagnosis of chronic osteomyelitis**” **Tumori**. 2015 Jun 25;101(3):e99-e102.
- **Griguolo G**, Stathis A “**BET inhibitors as potential anticancer agents**” **Drugs Fut** 2015, 40(6): 381
- Book chapter “Cardiac toxicity” in “ESMO Handbook of Oncological Emergencies” ESMO 2016
- Dieci MV, **Griguolo G**, Miglietta F, Guarneri V “The immune system and hormone-receptor positive breast cancer: Is it really a dead end?” **Cancer Treat Rev**. 2016 Mar 28;46:9-19.
- Gennari R, **Griguolo G**, Dieci MV, Guarneri V, Tavaniello B, Sibilio A, Conte P “**Fat grafting for breast cancer patients: From basic science to clinical studies**” **Eur J Surg Oncol**. 2016 Aug;42(8):1088-102
- **Griguolo G**, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V “**Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome**” **J Neurooncol**. 2017 Jan;131(2):369-376.
- Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, **Griguolo G**, Conte P, Guarneri V “**Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials**” **Breast Cancer Res Treat**. 2017 Jun;163(2):295-302.
- Stathis A, Hess D, von Moos R, Homicsko K, **Griguolo G**, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C; Swiss Group for Clinical Cancer Research (SAKK) “**Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors**” **Invest New Drugs**. 2017 Mar 20
- Carbognin L, Sperduti I, Fabi A, Dieci MV, Kadrija D, **Griguolo G**, Pilotto S, Guarneri V, Zampiva I, Brunelli M, Orvieto E, Nortilli R, Fiorio E, Parolin V, Manfrin E, Calì A, Nisticò C, Pellini F, Scarpa A, Pollini GP, Conte P, Tortora G, Bria E. “**Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation**” **Breast**. 2017 Jun 16;35:21-26.
- Miglietta F, Dieci MV, **Griguolo G**, Guarneri V, Conte PF. **Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?** **Cancer Treat Rev**. 2017 Nov;60:100-108.
- **Griguolo G**, Jacot W, Kantelhardt E, Dieci MV, Bourcier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A. **External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience**. **Breast**. 2017 Oct 23;37:36-41
- Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Olini C, Merlini L, Pasini F, Bonciarelli G, **Griguolo G**, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. **First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer**. **Oncologist**. 2018 Mar;23(3):297-305
- Darlix A, **Griguolo G**, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V. **Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer**. **J Neurooncol**. 2018 Feb 27.
- **Griguolo G**, Dieci MV, Guarneri V, Conte P. **Olaparib for the treatment of breast cancer**. **Expert Rev Anticancer Ther**. 2018 Mar 30;1-12.
- Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, **Griguolo G**, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V. **Immune characterization of breast cancer metastases: prognostic implications**. **Breast Cancer Res**. 2018 Jun 22;20(1):62.
- Dieci MV, Ghiotto C, Barbieri C, **Griguolo G**, Saccardi C, Gangemi M, Pluchinotta A, Di Liso E, Giorgi CA, Giarratano T, Tasca G, Vernaci G, Faggioni G, Conte P, Guarneri V. **Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center**. **J Womens Health (Larchmt)**. 2018 Jul 2. [Epub ahead of print]
- **Griguolo G**, Poudroux S, Dieci MV, Jacot W, Bourcier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A. **Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology**. **Oncologist**. 2018 Nov;23(11):1289-1299.
- Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galvan P, Ambroggi M, Giorgi CA, Moretti G, **Griguolo G**, Vicini R, Prat A, Conte PF. **De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study**. **Ann Oncol** 2019 Feb; ePub ahead of publication
- **Griguolo G**, Pascual T, Dieci MV, Guarneri V, Prat A. **Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer**. **J Immunother Cancer**. 2019 Mar 29;7(1):90.
- Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, **Griguolo G**, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF. **HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade**. **J Natl Cancer Inst**. 2019 Apr 30.

Language skills:

LANGUAGE	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
Italian	C2	C2	C2	C2	C2
English	C2	C2	C1	C1	C1
French	C1	C1	C1	B2	B2
Spanish	B2	B2	A2	A2	A2